Drug discovery today
-
Drug discovery today · Jul 2018
Review'Bioexit': navigating the policy and regulatory pathways for the biotechnology industry in a post-Brexit landscape.
The withdrawal of the UK from the European Union (EU) is a complicated event. Although implications vary by industry, the biotechnology sector is especially vulnerable to the consequences of Brexit. ⋯ We conclude that all four pathways fail to protect the mutually beneficial UK-EU biotechnology relationship and that alternative pathways need to be explored. Accordingly, we outline a suite of policy mechanisms aimed at ensuring continued EU-UK regulatory synergy, with the central aim of ensuring access to biomedical innovations and ensuring patient safety.